Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Ren, Fenglian ^a   Wu, Hong ^a   Lei, Yunlong ^a   Zhang, Haiyuan ^b   Liu, Rui ^a   Zhao, Yong ^a   Chen, Xiancheng ^a   Zeng, Dequan ^a   Tong, Aiping ^a   Chen, Lijuan ^a   Wei, Yuquan ^a   Huang, Canhua ^a  

^a SICHUAN UNIVERSITY   (China)

^b YANGTZE UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ISOMERASE; PHOSPHOGLYCERATE MUTASE 1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; PHOSPHOGLYCERATE MUTASE; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CHINA; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SURVIVAL RATE; UPREGULATION; ANIMAL; BIOSYNTHESIS; CANCER STAGING; CELL SEPARATION; DRUG SCREENING; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; NICK END LABELING; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOGLYCERATE MUTASE; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950919036     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-81     Document Type: Article

References (55)

1. Chen Y, Lin MC, Yao H, Wang H, Zhang A, Yu J, Hui CK, Lau GK, He M, Sung J, Kung H. Lentivirus-Mediated RNA interference targeting enhancer of Zeste Homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of Stathmin. Hepatology 2007, 46:200-208. 10.1002/hep.21668, 17596871.
2. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006, 25:3866-3884. 10.1038/sj.onc.1209550, 16799628.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterolog y 2007, 132:2557-2576.
4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16. 10.1053/j.gastro.2004.09.011, 15508102.
5. Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009, 29:10-17. 10.1111/j.1478-3231.2008.01916.x, 19120940.
6. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897-907. 10.1002/hep.22160, 18176954.
7. Hwang LH. Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci 2006, 13:453-468. 10.1007/s11373-006-9085-7, 16633742.
8. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72. 10.1016/S0968-0004(98)01344-9, 10098401.
9. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314. 10.1126/science.123.3191.309, 13298683.
10. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005, 65:177-185.
11. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646. 10.1038/sj.onc.1209597, 16892078.
12. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590. 10.1016/S0092-8674(03)00929-2, 14651849.
13. Engel M, Mazurek S, Eigenbrodt E, Welter C. Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines. J Biol Chem 2004, 279:35803-35812. 10.1074/jbc.M402768200, 15181008.
14. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol 2005, 23:1303-1307. 10.1038/nbt1149, 16200062.
15. de Atauria P, Repiso A, Oliva B, Vives-Corrons JL, Climent F, Carreras J. Characterization of the first described mutation of human red blood cell phosphoglycerate mutase. Biochim Biophys Acta 2005, 1740:403-410.
16. Zhang J, Yu L, Fu Q, Gao J, Xie Y, Chen J, Zhang P, Liu Q, Zhao S. Mouse phosphoglycerate mutase M and B isozymes: cDNA cloning, enzyme activity assay and mapping. Gene 2001, 264:273-279. 10.1016/S0378-1119(00)00597-7, 11250083.
17. Sakoda S, Shanske S, DiMauro S, Schon EA. Isolation of a cDNA encoding the B isozyme of human phosphoglycerate mutase (PGAM) and characterization of the PGAM gene family. J Biol Chem 1988, 263:16899-16905.
18. Betrán E, Wang W, Jin L, Long M. Evolution of the phosphoglycerate mutase processed gene in human and chimpanzee revealing the origin of a new primate gene. Mol Biol Evol 2002, 19:654-663.
19. Narayanan NK, Narayanan BA, Nixon DW. Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation. Cancer Detect Prev 2004, 28:443-452. 10.1016/j.cdp.2004.08.009, 15582268.
20. Durany N, Joseph J, Jimenez OM, Climent F, Fernández PL, Rivera F, Carreras J. Phosphoglycerate mutase, 2, 3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br J Cancer 2000, 82:20-27. 10.1054/bjoc.1999.0871, 2363199, 10638961.
21. Usuba T, Ishibashi Y, Okawa Y, Hirakawa T, Takada K, Ohkawa K. Purification and identification of monoubiquitin-phosphoglycerate mutase B complex from human colorectal cancer tissues. Int J Cancer 2001, 94:662-668. 10.1002/ijc.1524, 11745460.
22. Liu L, Wang S, Zhang Q, Ding Y. Identification of potential genes/proteins regulated by Tiam1 in colorectal cancer by microarray analysis and proteome analysis. Cell Biol Int 2008, 32:1215-1222. 10.1016/j.cellbi.2008.07.004, 18675922.
23. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ, Orringer MB, Hanash SM, Beer DG. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 2003, 23:13537-13542.
24. Li C, Xiao Z, Chen Z, Zhang X, Li J, Wu X, Li X, Yi H, Li M, Zhu G, Liang S. Proteome analysis of human lung squamous carcinoma. Proteomics 2006, 6:547-558. 10.1002/pmic.200500256, 16342241.
25. Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M. Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresi 2006, 27:1417-1423.
26. Fang MZ, Liu C, Song Y, Yang GY, Nie Y, Liao J, Zhao X, Shimada Y, Wang L, Yang CS. Over-expression of gastrin-releasing peptide in human esophageal squamous cell Carcinomas. Carcinogenesis 2004, 25:865-871. 10.1093/carcin/bgh097, 14764456.
27. Tong A, Wu L, Lin Q, Lau QC, Zhao X, Li J, Chen P, Chen L, Tang H, Huang C, Wei Y. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 2008, 8:2012-2023. 10.1002/pmic.200700849, 18491315.
28. Kuramitsu Y, Nakamura K. Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma. Expert Rev Proteomics 2005, 2:589-601. 10.1586/14789450.2.4.589, 16097891.
29. Ariizumi S, Katagiri S, Katsuragawa H, Kotera Y, Yamamoto M. Sectionectomy is suitable for patients with T2 hepatocellular carcinoma according to the modified international union against cancer TNM classification. Dig Surg 2007, 24:342-348. 10.1159/000107714, 17785977.
30. Jin X, Yang YD, Chen K, Lv ZY, Zheng L, Liu YP, Chen SH, Yu CH, Jiang XY, Zhang CY, Li YM. HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by decreasing ATP and H2O2 levels: a novel mechanism for NAFLD. J Hepatol 2009, 50:857-860. 10.1016/j.jhep.2008.10.034, 19328582.
31. Wei Y, Zhao X, Kariya Y, Teshigawara K, Uchida A. Inhibition of proliferation and induction of apoptosis by abrogation of heat-shock protein (HSP) 70 expression in tumor cells. Cancer Immunol Immunother 1995, 40:73-78. 10.1007/BF01520287, 7882385.
32. Li Z, Huang C, Bai S, Pan X, Zhou R, Wei Y, Zhao X. Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int J Cancer 2008, 123:2377-2383. 10.1002/ijc.23808, 18729184.
33. Zhou L, Jiang Y, Tan A, Greenlee AR, Shen Y, Liu L, Yang Q. Silencing of N-Ras gene expression using shRNA decreases transformation efficiency and tumor growth in transformed cells induced by anti-BPDE. Toxicol Sci 2008, 105:286-94. 10.1093/toxsci/kfn122, 18567617.
34. Bai Y, Deng H, Yang Y, Zhao X, Wei Y, Xie G, Li Z, Chen X, Chen L, Wang Y, Su D, Qian Z, Zhong Q, Luo H, Yi T. VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice. Oncology 2009, 77:385-394. 10.1159/000279385, 20130421.
35. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763. 10.1053/j.gastro.2008.02.090, 18471552.
36. Janke J, Schlüter K, Jandrig B, Theile M, Kölble K, Arnold W, Grinstein E, Schwartz A, Estevéz-Schwarz L, Schlag PM, Jockusch BM, Scherneck S. Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med 2000, 191:1675-1686. 10.1084/jem.191.10.1675, 2193149, 10811861.
37. Wu N, Zhang W, Yang Y, Liang Y, Wang L, Jin J, Cai X, Zha X. Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. Proteomics 2006, 6:6095-6106. 10.1002/pmic.200500321, 17051635.
38. Rigden DJ, Bagyan I, Lamani E, Setlow P, Jedrzejas MJ. A cofactor-dependent phosphoglycerate mutase homolog from Bacillus stearothermophilus is actually a broad specificity phosphatase. Protein Sci 2001, 10:1835-1846. 10.1110/ps.15701, 2253200, 11514674.
39. Fraser HI, Kvaratskhelia M, White MF. The two analogous phosphoglycerate mutases of Escherichia coli . FEBS Lett 1999, 455:344-348. 10.1016/S0014-5793(99)00910-2, 10437801.
40. Rafael MS, Encalada R, Alvaro MH, Saavedra E. Experimental validation of metabolic pathway modeling an illustration with glycolytic segments from Entamoeba histolytica. FEBS J 2008, 275:3454-3469. 10.1111/j.1742-4658.2008.06492.x, 18510554.
41. Gonzalez-Cinca N, Pérez de la Ossa P, Carreras J, Climent F. Effects of thyroid hormone and hypoxia on 2,3-Bisphosphoglycerate, bisphosphoglycerate synthase and phosphoglycerate mutase in rabbit erythroblasts and reticulocytes in vivo. Horm Res 2004, 62:191-196. 10.1159/000080897, 15375329.
42. Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, Oka M. Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol 2008, 33:725-731.
43. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899. 10.1038/nrc1478, 15516961.
44. Liu R, Li Z, Bai S, Zhang H, Tang M, Lei Y, Chen L, Liang S, Zhao Y, Wei Y, Huang C. Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics 2009, 8:70-85. 10.1074/mcp.M800195-MCP200, 18723843.
45. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, Zhou S, Califano JA, Jeoung NH, Harris RA, Verma A. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 2008, 283:22700-22708. 10.1074/jbc.M801765200, 2504897, 18541534.
46. Ortega AD, Sánchez-Aragó M, Giner-Sánchez D, Sánchez-Cenizo L, Willers I, Cuezva JM. Glucose avidity of carcinomas. Cancer Lett 2009, 276:125-135. 10.1016/j.canlet.2008.08.007, 18790562.
47. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009, 100:1369-1372. 10.1038/sj.bjc.6605007, 19352381.
48. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R, Bertrand L. AMPK: Lessons from transgenic and knockout animals. Front Biosci 2009, 14:19-44. 10.2741/3229, 2666987, 19273052.
49. Board M, Humm S, Newsholme EA. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 1990, 265:503-509. 1136912, 2302181.
50. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?. J Bioenerg Biomembr 2007, 39:251-257. 10.1007/s10863-007-9085-y, 17624581.
51. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001, 173:83-91. 10.1016/S0304-3835(01)00667-X, 11578813.
52. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
53. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment?. Mol Cancer Ther 2003, 2:573-580.
54. Kok JW, Sietsma H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 2004, 5:375-82. 10.2174/1389450043345452, 15134220.
55. Chi JT, Chang HY, Wang NN, Chang DS, Dunphy N, Brown PO. Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA 2003, 100:6343-6. 10.1073/pnas.1037853100, 164448, 12730368.